Results 51 to 60 of about 4,959 (174)
Lugol’s Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report
Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.Introduction Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol’s solution.
Mariam Mabrouk +7 more
wiley +1 more source
Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.Background Tirzepatide is a dual agonist of the glucose‐dependent insulinotropic polypeptide (GIP) receptor and glucagon‐like peptide‐1 (GLP‐1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity.
Yusuke Deto +8 more
wiley +1 more source
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang +6 more
wiley +1 more source
Treatment of Graves' ophthalmopathy
Клиническая и экспериментальная тиреоидология, 2010 Graves' ophthalmopathy is one of most frequent extrathyroid manifestation of autoimmune thyroid diseases. In 3–5% cases it has severe progress and requires specific therapy.
doaj +1 more source
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu +3 more
wiley +1 more source
Clinical Presentation of Graves’ Ophthalmopathy
Ophthalmic Research, 2009 The eye findings of Graves’ ophthalmopathy were prospectively recorded in 90 consecutive untreated patients (66 females, 24 males; mean age 44.5 years) according to the 1977 NOSPECS classification. Soft-tissue involvement was observed in 90%, proptosis ≥ 23 mm in 30%, eye muscle involvement in 60%, corneal involvement in 9% and sight loss in 34%.
Wiersinga, W. M. +4 more
openaire +3 more sources
Journal of Patient-Reported Outcomes, 2019 Purpose To develop and assess the psychometric properties of the Thai version of the Graves’ Ophthalmopathy Quality of Life (GO-QOL) questionnaire. Background Graves’ ophthalmopathy (GO) is a chronic condition that causes negative self-image and impaired
Mingkwan Lumyongsatien +8 more
doaj +1 more source
Folia Histochemica et Cytobiologica, 2009 The purpose of the study was to evaluate the percentage of CD4+/CD8+ peripheral T cells expressing CD62L+ and CD54+ in patients with Graves' disease and to assess if these estimations could be helpful as markers of active ophthalmopathy.
Alina Bakunowicz-Lazarczyk +4 more
doaj +1 more source
Bilateral severe Graves’ ophthalmopathy exacerbated by Ethiopian folk medicine: A case report
Indian Journal of Ophthalmology. Case ReportsThis case report discusses a 48-year-old Ethiopian patient with Graves’ ophthalmopathy who turned to an Ethiopian folk remedy involving medicinal smoke, leading to the exacerbation of Graves’ ophthalmopathy.
Konstantin Yaakov Gushansky +2 more
doaj +1 more source
Age Influences the Severity of Graves' Ophthalmopathy
Kaohsiung Journal of Medical Sciences, 2008 This study compared the ocular manifestations of Graves' disease in different age groups and between genders. This was a retrospective study with a chart review of 210 patients seen in the Kaohsiung Veterans General Hospital Ophthalmology Department from
Muh-Chiou Lin +3 more
doaj +1 more source